Test Drive 
, our AI Chatbot - get instant regulatory answers, free and live! Try Now
April 9, 2026 
Imagine this: In a regulatory review meeting, a team finds out about a major FDA guidance update three weeks after publication. Nobody flagged it earlier. Nobody had a system to flag it. The submission was already drafted around old assumptions. That can happen to a company of any size, and the cost can be a four-month setback or a re-do of substantial sections of their 510(k).
This is what the absence of Regulatory Intelligence for medical devices actually looks like in practice. Expensive and entirely avoidable.
Here’s a number worth sitting with: the FDA alone authorized over 1,000 AI-enabled medical devices as of late 2024, and 2025 saw 295 AI/ML 510(k) clearances in a single year. Every one of those clearances comes with a decision summary, a predicate chain, a set of special controls. And those are just the US approvals.
Across the EU, Japan, Brazil, China, and the ASEAN bloc, guidance documents, classification amendments, enforcement notices, and interpretive guidance from notified bodies are being published on a near-continuous basis. No regulatory affairs team, no matter how experienced, can monitor all of it manually and still have bandwidth left to actually file anything.
This is where medical device Regulatory Intelligence becomes a functional necessity. Not as a subscription dashboard you check once a month. As an active, curated intelligence process that feeds directly into product development decisions, submission planning, and market access strategy.
There’s a version of Regulatory Intelligence that’s essentially a glorified news alert. Someone subscribes to the Federal Register, a few agency RSS feeds, gets a weekly digest, and calls it done. That’s monitoring. Useful, but it stops well short of intelligence.
Real medical device Regulatory Intelligence operates across three distinct layers:
The first is environmental scanning: systematic monitoring of regulatory outputs from every authority relevant to your product portfolio. This includes not just FDA guidance documents and EU MDR updates, but notified body publications, IMDRF harmonization papers, MDCG guidance (the EU’s own coordination group published MDCG 2025-6 in June 2025 specifically clarifying how the AI Act interacts with the MDR), MHRA white papers, and warning letters that reveal enforcement priorities.
The second layer is impact analysis: This is where most teams fall short. Getting the information is one thing. Translating it into “here is what this means for our PMA supplement timeline” or “here is how this new classification rule affects three SKUs in our EU portfolio” requires someone with both regulatory depth and commercial context. It’s closer to analysis than research.
The third is dissemination: getting the right intelligence to the right people, formatted in a way they can act on. A clinical evidence gap summary for the CMO reads very differently from a timeline impact brief for the CFO. Both need the same underlying intelligence. Neither gets value from a raw PDF of a Federal Register notice.
The EU MDR story is worth examining in detail, because it illustrates both the cost of poor Regulatory Intelligence and the consequences of regulatory change happening faster than the industry can absorb it.
The transitional period under the MDR has already been extended multiple times. As of October 2025, only 51 notified bodies held MDR designation, facing a queue of over 20,000 applications. Average review times are running 13 to 18 months, with complex devices often taking longer. Manufacturers who assumed the extended deadlines meant they could slow their compliance activities are now realizing that submitting one year before a deadline is, in practice, too late to guarantee certification in time.
Then in December 2025, the European Commission released a 170-page proposal to simplify the MDR and IVDR. The proposal includes reclassifying some software from Class IIa down to Class I (removing notified body involvement), introducing maximum timelines for conformity assessment, and streamlining requirements for well-established technology devices. It has also been widely misread.
The legislative process for that proposal won’t yield a final regulation before Q2 2027, at the earliest. Companies using it as a reason to pause MDR compliance activities are making a miscalculation that their Regulatory Intelligence function should be correcting in real time.
This is precisely the kind of situation where EU MDR Regulatory Intelligence has direct commercial value, separating the signal (the direction of travel) from the noise (don’t wait on it).
We want to push back on something that comes up often in regulatory affairs discussions. The framing that Regulatory Intelligence is fundamentally a risk-mitigation activity. It is, partly. But the more interesting application is competitive.
Consider the FDA’s January 2025 Draft Guidance on AI-Enabled Device Software Functions. Buried in that document are specific recommendations on labeling transparency for AI/ML models stating the device uses AI, describing model inputs and outputs, disclosing known sources of bias. Most companies are reading this as a compliance checklist for future submissions.
A company with a strong Regulatory Intelligence function reads it differently. They see it as a signal that FDA reviewers are going to scrutinize these elements more closely in near-term submissions. They adjust their technical documentation strategy six months before the guidance is finalized. They get cleaner submissions with fewer Additional Information requests. They close deals faster because their regulatory timeline is shorter and more predictable.
A 2024 survey cited by MedTech Intelligence found that 89% of investors now consider Regulatory Intelligence a vital input to due diligence. Investors aren’t asking because they enjoy asking. They’re asking because regulatory miscalculation is one of the most common failure modes in MedTech startups.
AI in medical device compliance has moved from experimental to operational over the last two years. Platforms are now doing things that were genuinely not possible at scale five years ago: monitoring regulatory agency websites across hundreds of markets simultaneously, flagging guidance documents relevant to a specific device category using NLP, and auto-generating impact summaries when standards are updated.
The FDA itself began deploying generative AI internally in May 2025 across all centers and rolled out an agentic AI system in December 2025 to support pre-market review and compliance monitoring. The agency is doing this partly because its staffing levels dropped and reviewer bandwidth is constrained. The Q-Submission process, pre-sub meetings to get informal FDA feedback before filing has become more valuable precisely because of this.
But there’s a limitation worth being honest about. A 2025 Analysis found that regulatory database quality and accessibility remain fundamental constraints on AI-driven oversight. The AI layer is only as reliable as the curated, verified intelligence it sits on top of. Automated scanning of low-quality or incomplete data produces low-quality intelligence, faster. The editorial layer – expert curation, jurisdictional context, impact analysis still requires human judgment.
Medical device compliance automation handles the volume. Human expertise handles the interpretation. The best Regulatory Intelligence tools for devices are built around that combination, not a replacement of one by the other.
For manufacturers building or refining this capability, the architecture isn’t complicated, but the discipline required to maintain it is often underestimated.
At a minimum, a working regulatory strategy for medical devices supported by solid intelligence infrastructure includes:
The healthcare compliance software market, which captures much of this infrastructure spend, was valued at $3.92 billion in 2025 and is projected to reach $6.80 billion by 2030. That’s a meaningful signal about where the industry is heading.
Based on our interactions with our clients, one thing that can change about how most MedTech companies resource Regulatory Intelligence, it’s this: stop treating it as overhead.
In Q1 2025, venture funding for medical devices hit $2.6 billion. Investors are explicitly pricing regulatory risk into their models. A company that can demonstrate clear-eyed, current, accurate knowledge of its regulatory pathway with contingencies, with timeline ranges, with awareness of the specific draft guidances that might affect its submission commands a fundamentally different conversation at the term sheet stage than one that can’t.
Regulatory Intelligence doesn’t just reduce risk. Done right, it shortens time to market, which in this industry often means the difference between entering a category first and entering it third. The information fragmentation cost – missed updates, reactive compliance, delayed submissions compounds quietly until it shows up as a number on a board deck that’s hard to explain.
This is the gap that freya.intelligence, our AI-powered Regulatory Intelligence platform, was purpose-built to close.
It gives regulatory affairs professionals, quality teams, and MedTech executives direct access to curated, current, verified intelligence on verified global medical device regulations without the hours of manual monitoring, without the consultant fees, without the lag.
Ask Freya (our AI-powered regulatory advisor) how the December 2025 MDR simplification proposal affects your Class IIb device. Ask it to walk you through the PCCP requirements for an adaptive AI algorithm. Ask it what the FDA’s January 2025 draft guidance means for your next 510(k) submission. It gives you context-specific, source-backed answers drawn from verified regulatory content build by Freyr over the past 15+ years, in plain language.
This is Regulatory Intelligence for medical devices without the overhead of a full monitoring infrastructure and without the risk of working from outdated information.
Start your 14-day free trial and see what it’s like to have the right answer to a compliance question in two minutes rather than two days.
Get your regulatory dose of information delivered straight to your inbox every month!
Subscribe Now
